Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRHDE | Q9UKU6 | 1/20 | 0.52 |
| ▸ | ITGB3 | P05106 | 10/20 | 0.49 |
| ▸ | ITGA2B | P08514 | 10/20 | 0.49 |
| ▸ | PPARA | Q07869 | 3/20 | 0.47 |
| ▸ | PPARG | P37231 | 1/20 | 0.47 |
| ▸ | CTSL | P07711 | 2/20 | 0.46 |
| ▸ | CTSB | P07858 | 2/20 | 0.46 |
| ▸ | CTSS | P25774 | 2/20 | 0.46 |
| ▸ | TACR1 | P25103 | 2/20 | 0.46 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.45 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18468298 | 0.89 | ITGB3 (0.48) | ITGB3ITGA2BPPARAPPARGCTSL | |
| SCHEMBL755381 | 0.89 | TRHDE (0.54) | TRHDEITGA4ITGB7 | |
| SCHEMBL1430994 | 0.87 | ITGB3 (0.46) | ITGB3ITGA2BCTSLCTSBCTSS | |
| SCHEMBL2215563 | 0.87 | ITGB3 (0.46) | ITGB3ITGA2BCTSLCTSBCTSS | |
| SCHEMBL17642069 | 0.85 | ACE (0.56) | TRHDEITGB3ITGA2BPPARAPPARG | |
| SCHEMBL3429311 | 0.85 | ACE (0.56) | TRHDEITGB3ITGA2BPPARAPPARG | |
| SCHEMBL9394394 | 0.84 | ITGB3 (0.52) | ITGB3ITGA2BCTSLCTSBCTSS | |
| SCHEMBL29589719 | 0.84 | MDM4 (0.54) | TRHDE | |
| SCHEMBL29400706 | 0.84 | MDM4 (0.54) | TRHDE | |
| SCHEMBL30234099 | 0.84 | MDM4 (0.54) | TRHDE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240285724-A1 | METHODS AND COMPOSITIONS FOR TREATING OCULAR DISORDERS AND DISEASES | ONL THERAPEUTICS, INC. | 2024-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240285724-A1 | METHODS AND COMPOSITIONS FOR TREATING OCULAR DISORDERS AND DISEASES | NFKBIA, ALDH1A2, ALOX5 | TRHDE 4165/4885ITGB3 1618/4885ITGA2B 1538/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.